EU backs AstraZeneca, Daiichi's ENHERTU

Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant and clinically meaningful improvement in main goal for its gastric or gastroesophageal junction cancer trial.
EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients
AstraZeneca Enhertu recommended for approval in EU by CHMP
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the treatment of metastatic breast cancer. Issuing a positive recommendation, EMA’s Committee for Medicinal Products for Human Use (CHMP)  recommended the marketing authorization for ENHERTUas a monotherapy for the treatment of
FiercePharma6h
AstraZeneca, Daiichi unblind Enhertu study early as star ADC helps stomach cancer patients live longer
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
BioPharma Dive9h
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...
Cure Today12d
Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer
Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...
pharmaphorum2d
Enhertu gets first okay for HER2-ultralow breast cancer
AstraZeneca and Daiichi Sankyo have claimed their seventh FDA approval for Enhertu, getting the go-ahead for the blockbuster drug as a second-line treatment for patients with HER2-low and HER2 ...
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy ...
At Rs 58 crore, cancer drug emerges top seller among new launches in 2024
Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectiv ...
pharmaphorum2d
Enhertu cleared for NHS use via Cancer Drugs Fund
AZ licensed rights to Enhertu in 2019 for a hefty $1.35 billion upfront in a deal that could be worth up to $6.9 billion if all the ADC’s development and sales objectives are achieved.